Table 1.
Raw data and statistics stratified by COL vs non-COL mutation.
| COL groups | ||||
|---|---|---|---|---|
|
COL
(N = 268) |
Non-COL
(N = 26) |
Total
(N = 294) |
p-value | |
| Sex, n (%) | 0.22a | |||
| Female | 131 (48.9%) | 16 (61.5%) | 147 (50.0%) | |
| Male | 137 (51.1%) | 10 (38.5%) | 147 (50.0%) | |
| Race, n (%) | 0.004 b | |||
| White | 209 (78.0%) | 13 (50.0%) | 222 (75.5%) | |
| Non-White | 59 (22.0%) | 13 (50.0%) | 72 (24.5%) | |
| Autism, n (%) | 4 (1.5%) | 2 (7.7%) | 6 (2.0%) | 0.09b |
| Expressive language disorder/delay, n (%) | 1 (0.4%) | 4 (15.4%) | 5 (1.7%) | 0.0002 b |
| Blue sclera, n (%) | 221 (82.5%) | 15 (57.7%) | 236 (80.3%) | 0.002 a |
| Dentinogenesis imperfecta, n (%) | 131 (48.9%) | 4 (15.4%) | 135 (45.9%) | 0.0009 b |
| Age at first hearing loss diagnosis, mean (SD) | 8.6 (6.16) | 3.8 (2.99) | 8.2 (6.09) | 0.13c |
| Age at first bisphosphonate infusion, mean (SD) | 3.9 (4.52) | 2.5 (3.36) | 3.7 (4.44) | 0.39c |
| Age at DEXA, mean (SD) | 11.4 (5.10) | 8.9 (4.59) | 11.2 (5.10) | 0.02 d |
| Patient received bisphosphonates at time of DEXA, n (%) | 231 (87.5%) | 26 (100.0%) | 257 (88.6%) | 0.05b |
| DEXA Z-score, mean (SD) | −1.1 (1.73) | −0.9 (2.08) | −1.1 (1.76) | 0.68d |
| Family history of OI, n (%) | 91 (34.0%) | 3 (11.5%) | 94 (32.0%) | 0.03 b |
| History of scoliosis, n (%) | 108 (40.4%) | 16 (61.5%) | 124 (42.3%) | 0.04 a |
| Scoliosis operations, n (%) | 21 (19.4%) | 1 (6.3%) | 22 (17.7%) | 0.30b |
| History of rod placement for long bone deformity, n (%) | 184 (68.7%) | 20 (76.9%) | 204 (69.4%) | 0.38a |
| Presence of joint hypermobility, n (%) | 207 (77.2%) | 21 (80.8%) | 228 (77.6%) | 0.68a |
| Patient diagnosed short in stature, n (%) | 145 (54.1%) | 19 (73.1%) | 164 (55.8%) | 0.06a |
aChi-square p-value;
bFisher Exact p-value;
cWilcoxon rank sum p-value;
dEqual variance 2 sample t-test.
Abbreviations: DEXA, Dual-Energy X-ray Absorptiometry; SD, standard deviation. Bolded values are the statistically significant values.